|
1
|
Farmakis D: Anticoagulation for atrial
fibrillation in active cancer: What the cardiologists think. Eur J
Prev Cardiol. 28:608–610. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vedovati MC, Giustozzi M, Verdecchia P,
Pierpaoli L, Conti S, Verso M, Di Filippo F, Marchesini E, Bogliari
G, Agnelli G and Becattini C: Patients with cancer and atrial
fibrillation treated with doacs: A prospective cohort study. Int J
Cardiol. 269:152–157. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Farmakis D, Parissis J and Filippatos G:
Insights into onco-cardiology: Atrial fibrillation in cancer. J Am
Coll Cardiol. 63:945–953. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hindricks G, Potpara T, Dagres N, Arbelo
E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA,
Dilaveris PE, et al: 2020 ESC Guidelines for the diagnosis and
management of atrial fibrillation developed in collaboration with
the European Association of Cardio-Thoracic Surgery (EACTS): The
Task Force for the diagnosis and management of atrial fibrillation
of the European Society of Cardiology (ESC) Developed with the
special contribution of the European Heart Rhythm Association
(EHRA) of the ESC. Eur Heart J. 42:373–498. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hu YF, Chen TC, Chau GY, Yang TL, Liu CJ,
Chen MH, Chang PM, Chen TJ, Hsiao M, Huang CY and Chen SA: Baseline
hypertension: New insight into the potential predictors of survival
in patients with hepatocellular carcinoma. Int J Cardiol.
168:2979–2981. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
NICE, . Venous thromboembolism in adults.
Quality standard [QS201]. https://www.nice.org.uk/guidance/qs201/resources/venous-thromboembolism-in-adults-pdf-75547409387461February
17–2022
|
|
7
|
Khorana AA, Noble S, Lee AYY, Soff G,
Meyer G, O'Connell C and Carrier M: Role of direct oral
anticoagulants in the treatment of cancer-associated venous
thromboembolism: Guidance from the SSC of the ISTH. J Thromb
Haemost. 16:1891–1894. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sato T, Aizawa Y, Fuse K, Fujita S, Ikeda
Y, Kitazawa H, Takahashi M and Okabe M: The impact of cancer on
major bleeding and stroke/systemic emboli in patients using direct
oral anticoagulants: From the database of a single-center registry.
J Atrial Fibrillation. 11:21052018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Khorana AA, Francis CW, Culakova E,
Kuderer NM and Lyman GH: Thromboembolism is a leading cause of
death in cancer patients receiving outpatient chemotherapy. J
Thromb Haemost. 5:632–634. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Khorana AA: Venous thromboembolism and
prognosis in cancer. Thrombosis Res. 125:490–493. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Elting LS, Escalante CP, Cooksley C,
Avritscher EB, Kurtin D, Hamblin L, Khosla SG and Rivera E:
Outcomes and cost of deep venous thrombosis among patients with
cancer. Arch Intern Med. 164:1653–1661. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sheard L, Prout H, Dowding D, Noble S,
Watt I, Maraveyas A and Johnson M: Barriers to the diagnosis and
treatment of venous thromboembolism in advanced cancer patients: A
qualitative study. Palliat Med. 27:339–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seaman S, Nelson A and Noble S:
Cancer-associated thrombosis, low-molecular-weight heparin, and the
patient experience: A qualitative study. Patient Prefer Adherence.
8:453–461. 2014.PubMed/NCBI
|
|
14
|
Khorana AA, Dalal MR, Lin J and Connolly
GC: Health care costs associated with venous thromboembolism in
selected high-risk ambulatory patients with solid tumors undergoing
chemotherapy in the United States. Clinicoecon Outcomes Res.
5:101–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Puurunen MK, Gona PN, Larson MG, Murabito
JM, Magnani JW and O'Donnell CJ: Epidemiology of venous
thromboembolism in the Framingham Heart Study. Thrombosis Res.
145:27–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Walker AJ, Card TR, West J, Crooks C and
Grainge MJ: Incidence of venous thromboembolism in patients with
cancer-a cohort study using linked United Kingdom databases. Eur J
Cancer. 49:1404–1413. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chew HK, Wun T, Harvey D, Zhou H and White
RH: Incidence of venous thromboembolism and its effect on survival
among patients with common cancers. Arch Intern Med. 166:458–464.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Abdol Razak NB, Jones G, Bhandari M,
Berndt MC and Metharom P: Cancer-associated thrombosis: An overview
of mechanisms, risk factors, and treatment. Cancers (Basel).
10:3802018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Navi BB, Reiner AS, Kamel H, Iadecola C,
Okin PM, Elkind MSV, Panageas KS and DeAngelis LM: Risk of arterial
thromboembolism in patients with cancer. J Am Coll Cardiol.
70:926–938. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Donnellan E and Khorana AA: Cancer and
venous thromboembolic disease: A review. Oncologist. 22:199–207.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ay C, Pabinger I and Cohen AT:
Cancer-associated venous thromboembolism: Burden, mechanisms, and
management. Thromb Haemost. 117:219–230. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mosarla RC, Vaduganathan M, Qamar A,
Moslehi J, Piazza G and Giugliano RP: Anticoagulation strategies in
patients with cancer: JACC review topic of the week. J Am Coll
Cardiol. 73:1336–1349. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Khorana AA and Connolly GC: Assessing risk
of venous thromboembolism in the patient with cancer. J Clin Oncol.
27:4839–4847. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
January CT, Wann LS, Calkins H, Chen LY,
Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME,
Furie KL, et al: 2019 AHA/ACC/HRS Focused Update of the 2014
AHA/ACC/HRS Guideline for the management of patients with atrial
fibrillation: A report of the American College of
Cardiology/American Heart Association Task Force on Clinical
Practice Guidelines and the Heart Rhythm Society. J Am Coll
Cardiol. 74:104–132. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Farmakis D and Filippatos G: Arrhythmias
in cancer: Rhythm is gonna get you! Eur J Heart Fail. 23:154–156.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim LK, Swaminathan RV, Looser P,
Minutello RM, Wong SC, Bergman G, Naidu SS, Gade CL, Charitakis K,
Singh HS and Feldman DN: Hospital volume outcomes after septal
myectomy and alcohol septal ablation for treatment of obstructive
hypertrophic cardiomyopathy: US Nationwide Inpatient Database,
2003-2011. JAMA Cardiol. 1:324–332. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Onaitis M, D'Amico T, Zhao Y, O'Brien S
and Harpole D: Risk factors for atrial fibrillation after lung
cancer surgery: Analysis of the Society of Thoracic Surgeons
general thoracic surgery database. Ann Thorac Surg. 90:368–374.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ostenfeld EB, Erichsen R, Pedersen L,
Farkas DK, Weiss NS and Sorensen HT: Atrial fibrillation as a
marker of occult cancer. PLoS One. 9:e1028612014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vinter N, Christesen AMS, Fenger-Gron M,
Tjonneland A and Frost L: Atrial fibrillation and risk of cancer: A
danish population-based cohort study. J Am Heart Assoc.
7:e0095432018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Conen D, Wong JA, Sandhu RK, Cook NR, Lee
IM, Buring JE and Albert CM: Risk of malignant cancer among women
with new-onset atrial fibrillation. JAMA Cardiol. 1:389–396. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Farmakis D, Parissis J, Karavidas A,
Karvounis C, Triposkiadis F, Filippatos G and Lekakis J;
Collaborators: In-hospital management of acute heart failure:
Practical recommendations and future perspectives. Int J Cardiol.
201:231–236. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Papanastasiou A, Morsi-Yeroyannis A,
Karagiannidis E, Kartas A, Doundoulakis I, Karvounis H and
Giannakoulas G: Association of anticoagulant-related bleeding
events with cancer detection in atrial fibrillation: A systematic
review and meta-analysis. Hellenic J Cardiol. 62:359–365. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chu G, Versteeg HH, Verschoor AJ, Trines
SA, Hemels ME, Ay C, Huisman MV and Klok FA: Atrial fibrillation
and cancer-An unexplored field in cardiovascular oncology. Blood
Rev. 35:59–67. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Keramida K, Filippatos G and Farmakis D:
Cancer treatment and atrial fibrillation: Use of pharmacovigilance
databases to detect cardiotoxicity. Eur Heart J Cardiovasc
Pharmacother. 7:321–323. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Alexandre J, Salem JE, Moslehi J, Sassier
M, Ropert C, Cautela J, Thuny F, Ederhy S, Cohen A, Damaj G, et al:
Identification of anticancer drugs associated with atrial
fibrillation: Analysis of the WHO pharmacovigilance database. Eur
Heart J Cardiovasc Pharmacother. 7:312–320. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Alexandre J, Moslehi JJ, Bersell KR,
Funck-Brentano C, Roden DM and Salem JE: Anticancer drug-induced
cardiac rhythm disorders: Current knowledge and basic underlying
mechanisms. Pharmacol Ther. 189:89–103. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Watson T, Shantsila E and Lip GY:
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's
triad revisited. Lancet. 373:155–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sethi G, Shanmugam MK, Ramachandran L,
Kumar AP and Tergaonkar V: Multifaceted link between cancer and
inflammation. Biosci Rep. 32:1–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Piazza G and Ridker PM: Is venous
thromboembolism a chronic inflammatory disease? Clin Chemistry.
61:313–316. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Morrell CN, Hilt ZT, Pariser DN and Maurya
P: PAD4 and von Willebrand Factor Link Inflammation and Thrombosis.
Circ Res. 125:520–522. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rickles FR, Patierno S and Fernandez PM:
Tissue factor, thrombin, and cancer. Chest. 124 (Suppl 3):58S–68S.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mousa SA: Anticoagulants in thrombosis and
cancer: The missing link. Semin Thromb Hemost. 28:45–52. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Allavena P, Garlanda C, Borrello MG, Sica
A and Mantovani A: Pathways connecting inflammation and cancer.
Curr Opin Genet Dev. 18:3–10. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Farmakis D, Chrysohoou C, Giamouzis G,
Giannakoulas G, Hamilos M, Naka K, Tzeis S, Xydonas S, Karavidas A
and Parissis J: The management of atrial fibrillation in heart
failure: An expert panel consensus. Heart Fail Rev. 26:1345–1358.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Leiva O, AbdelHameid D, Connors JM, Cannon
CP and Bhatt DL: Common pathophysiology in cancer, atrial
fibrillation, atherosclerosis, and thrombosis: JACC: CardioOncology
State-of-the-Art review. JACC CardioOncol. 3:619–634. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Saghazadeh A, Hafizi S and Rezaei N:
Inflammation in venous thromboembolism: Cause or consequence? Int
Immunopharmacol. 28:655–665. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bikdeli B, Abou Ziki MD and Lip GYH:
Pulmonary embolism and atrial fibrillation: Two sides of the same
Coin? A systematic review. Semin Thromb Hemost. 43:849–863. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Melloni C, Shrader P, Carver J, Piccini
JP, Thomas L, Fonarow GC, Ansell J, Gersh B, Go AS, Hylek E, et al:
Management and outcomes of patients with atrial fibrillation and a
history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care
Clin Outcomes. 3:192–197. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pastori D, Marang A, Bisson A, Menichelli
D, Herbert J, Lip GYH and Fauchier L: Thromboembolism, mortality,
and bleeding in 2,435,541 atrial fibrillation patients with and
without cancer: A nationwide cohort study. Cancer. 127:2122–2129.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kraaijpoel N and Carrier M: How I treat
cancer-associated venous thromboembolism. Blood. 133:291–298. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Min JS and Bae SK: Prediction of drug-drug
interaction potential using physiologically based pharmacokinetic
modeling. Arch Pharm Res. 40:1356–1379. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
van Leeuwen RW, Brundel DH, Neef C, van
Gelder T, Mathijssen RH, Burger DM and Jansman FG: Prevalence of
potential drug-drug interactions in cancer patients treated with
oral anticancer drugs. Br J Cancer. 108:1071–1078. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lechat P, Bergmann JF, Hanon PO, Beauvais
F, Pol S, Cavagna F, Sicard J, Janus N, Deray G and Launay-Vacher
V: Étude IPOP: Analyse qualitative et quantitative sur le risque
iatrogénique chez les sujets âgés en France, en médecine de ville.
La Lettre du Pharmacologue. 30:76–82. 2016.(In French).
|
|
54
|
Lee JY, Oh IY, Lee JH, Kim SY, Kwon SS,
Yang HJ, Kim YK and Bang SM: The increased risk of bleeding due to
drug-drug interactions in patients administered direct oral
anticoagulants. Thromb Res. 195:243–249. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ebner M, Birschmann I, Peter A, Härtig F,
Spencer C, Kuhn J, Rupp A, Blumenstock G, Zuern CS, Ziemann U and
Poli S: Limitations of specific coagulation tests for direct oral
anticoagulants: A critical analysis. J Am Heart Assoc.
7:e0098072018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Boriani G, Lee G, Parrini I,
Lopez-Fernandez T, Lyon AR, Suter T, Van der Meer P, Cardinale D,
Lancellotti P, Zamorano JL, et al: Anticoagulation in patients with
atrial fibrillation and active cancer: An international survey on
patient management. Eur J Prev Cardiol. 28:611–621. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Russo AM: Anticoagulation in cancer
patients with atrial fibrillation or atrial flutter: Are there gaps
in care? JACC CardioOncol. 2:755–757. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Pangilinan JM, Pangilinan PH Jr and Worden
FP: Use of warfarin in the patient with cancer. J Support Oncol.
5:131–136. 2007.PubMed/NCBI
|
|
59
|
Ambrus DB, Reisman JI and Rose AJ: The
impact of new-onset cancer among veterans who are receiving
warfarin for atrial fibrillation and venous thromboembolism. Thromb
Res. 144:21–26. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lee YJ, Park JK, Uhm JS, Kim JY, Pak HN,
Lee MH, Sung JH and Joung B: Bleeding risk and major adverse events
in patients with cancer on oral anticoagulation therapy. Int J
Cardiol. 203:372–378. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Delluc A, Wang TF, Yap ES, Ay C, Schaefer
J, Carrier M and Noble S: Anticoagulation of cancer patients with
non-valvular atrial fibrillation receiving chemotherapy: Guidance
from the SSC of the ISTH. J Thromb Haemost. 17:1247–1252. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lee AY, Levine MN, Baker RI, Bowden C,
Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, et
al: Low-molecular-weight heparin versus a coumarin for the
prevention of recurrent venous thromboembolism in patients with
cancer. N Engl J Med. 349:146–153. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Lee AYY, Kamphuisen PW, Meyer G,
Bauersachs R, Janas MS, Jarner MF and Khorana AA; CATCH
Investigators, : Tinzaparin vs warfarin for treatment of acute
venous thromboembolism in patients with active cancer: A randomized
clinical trial. JAMA. 314:677–686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zhang N, Lou W, Ji F, Qiu L, Tsang BK and
Di W: Low molecular weight heparin and cancer survival: clinical
trials and experimental mechanisms. J Cancer Res Clin Oncol.
142:1807–1816. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Pfankuchen DB, Stolting DP, Schlesinger M,
Royer HD and Bendas G: Low molecular weight heparin tinzaparin
antagonizes cisplatin resistance of ovarian cancer cells. Biochem
Pharmacol. 97:147–157. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Bokas A, Papakotoulas P, Sarantis P,
Papadimitropoulou A, Papavassiliou AG and Karamouzis MV: Mechanisms
of the antitumor activity of low molecular weight heparins in
pancreatic adenocarcinomas. Cancers (Basel). 12:4322020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Poterucha TJ, Libby P and Goldhaber SZ:
More than an anticoagulant: Do heparins have direct
anti-inflammatory effects? Thromb Haemost. 117:437–444. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Klerk CP, Smorenburg SM, Otten HM, Lensing
AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van
Tienhoven G and Büller HR: The effect of low molecular weight
heparin on survival in patients with advanced malignancy. J Clin
Oncol. 23:2130–2135. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Calvo Romero JM: Low-molecular-weight
heparins in patients with atrial fibrillation. Rev Clini Esp
(Barc). 217:151–154. 2017.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Steinberg BA, Peterson ED, Kim S, Thomas
L, Gersh BJ, Fonarow GC, Kowey PR, Mahaffey KW, Sherwood MW, Chang
P, et al: Use and outcomes associated with bridging during
anticoagulation interruptions in patients with atrial fibrillation:
Findings from the Outcomes Registry for Better Informed Treatment
of Atrial Fibrillation (ORBIT-AF). Circulation. 131:488–494. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Stellbrink C: Quick, easy, and safe? On
the use of low-molecular-weight heparins in cardioversion of atrial
fibrillation. Eur Heart J. 27:2742–2743. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Noble S, Matzdorff A, Maraveyas A, Holm MV
and Pisa G: Assessing patients' anticoagulation preferences for the
treatment of cancer-associated thrombosis using conjoint
methodology. Haematologica. 100:1486–1492. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Konstantinides SV, Meyer G, Becattini C,
Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings
CS, Jiménez D, et al: 2019 ESC Guidelines for the diagnosis and
management of acute pulmonary embolism developed in collaboration
with the European Respiratory Society (ERS). Eur Heart J.
41:543–603. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Agnelli G, Becattini C, Meyer G, Muñoz A,
Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki
A, et al: Apixaban for the treatment of venous thromboembolism
associated with cancer. N Engl J Med. 382:1599–1607. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Sabatino J, Rosa SD, Polimeni A,
Sorrentino S and Indolfi C: Direct Oral anticoagulants in patients
with active cancer: A systematic review and Meta-analysis. JACC
CardioOncol. 2:428–440. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Key NS, Khorana AA, Kuderer NM, Bohlke K,
Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW,
et al: Venous thromboembolism prophylaxis and treatment in patients
with cancer: ASCO Clinical practice guideline update. J Clin Oncol.
38:496–520. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Raskob GE, van Es N, Verhamme P, Carrier
M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri
MF, et al: Edoxaban for the treatment of cancer-associated venous
thromboembolism. N Engl J Med. 378:615–624. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Chen ST, Hellkamp AS, Becker RC, Berkowitz
SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ,
Mahaffey KW, et al: Efficacy and safety of rivaroxaban vs. warfarin
in patients with non-valvular atrial fibrillation and a history of
cancer: Observations from ROCKET AF. Eur Heart J Qual Care Clini
Outcomes. 5:145–152. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Melloni C, Dunning A, Granger CB, Thomas
L, Khouri MG, Garcia DA, Hylek EM, Hanna M, Wallentin L, Gersh BJ,
et al: Efficacy and safety of apixaban versus warfarin in patients
with atrial fibrillation and a history of cancer: Insights from the
ARISTOTLE trial. Am J Med. 130:1440–1448.e1. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Fanola CL, Ruff CT, Murphy SA, Jin J,
Duggal A, Babilonia NA, Sritara P, Mercuri MF, Kamphuisen PW,
Antman EM, et al: Efficacy and safety of edoxaban in patients with
active malignancy and atrial fibrillation: Analysis of the ENGAGE
AF-TIMI 48 trial. J Am Heart Assoc. 7:e0089872018. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Shah S, Norby FL, Datta YH, Lutsey PL,
MacLehose RF, Chen LY and Alonso A: Comparative effectiveness of
direct oral anticoagulants and warfarin in patients with cancer and
atrial fibrillation. Blood Adv. 2:200–209. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Sawant AC, Kumar A, Mccray W, Tetewsky S,
Parone L, Sridhara S, Prakash MPH, Tse G, Liu T, Kanwar N, et al:
Superior safety of direct oral anticoagulants compared to Warfarin
in patients with atrial fibrillation and underlying cancer: A
national veterans affairs database study. J Geriatr Cardiol.
6:706–709. 2019.PubMed/NCBI
|
|
83
|
Mariani MV, Magnocavallo M, Straito M,
Piro A, Severino P, Iannucci G, Chimenti C, Mancone M, Rocca DGD,
Forleo GB, et al: Direct oral anticoagulants versus vitamin K
antagonists in patients with atrial fibrillation and cancer a
meta-analysis. J Thromb Thrombolysis. 51:419–429. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Deng Y, Tong Y, Deng Y, Zou L, Li S and
Chen H: Non-Vitamin K antagonist oral anticoagulants versus
warfarin in patients with cancer and atrial fibrillation: A
systematic review and meta-analysis. J the Am Heart Assoc.
8:e0125402019. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Steffel J, Verhamme P, Potpara TS,
Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke
H, Roldan-Schilling V, et al: The 2018 European Heart Rhythm
association practical guide on the use of non-vitamin K antagonist
oral anticoagulants in patients with atrial fibrillation. Eur Heart
J. 39:1330–1393. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Tarn DM, Barrientos M, Wang AY, Ramaprasad
A, Fang MC and Schwartz JB: Prevalence and knowledge of potential
interactions between over-the-counter products and apixaban. J Am
Geriat Soc. 68:155–162. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Lopez-Fernandez T, Martin-Garcia A, Roldan
Rabadan I, Mitroi C, Mazón Ramos P, Díez-Villanueva P, Escobar
Cervantes C, Alonso Martín C, Alonso Salinas GL, Arenas M, et al:
Atrial fibrillation in active cancer patients: Expert position
paper and recommendations. Rev Esp Cardiol (Engl Ed). 72:749–759.
2019.(in English, Spanish). PubMed/NCBI
|
|
88
|
Zamorano JL, Lancellotti P, Rodriguez
Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ,
Lip GYH, Lyon AR, et al: 2016 ESC Position Paper on cancer
treatments and cardiovascular toxicity developed under the auspices
of the ESC Committee for Practice Guidelines: The Task Force for
cancer treatments and cardiovascular toxicity of the European
Society of Cardiology (ESC). Eur Heart J. 37:2768–2801. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Fradley MG, Ellenberg K, Alomar M, Swanson
J, Kharod A, Nguyen ATH, Khodor S, Mishra S, Duong LM, Shah N, et
al: Patterns of anticoagulation use in patients with cancer with
atrial fibrillation and/or atrial flutter. JACC CardioOncol.
2:747–754. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Malavasi VL, Fantecchi E, Gianolio L,
Pesce F, Longo G, Marietta M, Cascinu S, Lip GYH and Boriani G:
Atrial fibrillation in patients with active malignancy and use of
anticoagulants: Under-prescription but no adverse impact on
all-cause mortality. Eur J Intern Med. 59:27–33. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Farmakis D: Is cardio-oncology a rapidly
growing field of precision medicine? Eur J Heart Fail.
22:2310–2313. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Farmakis D, Keramida K and Filippatos G:
How to build a cardio-oncology service? Eur J Heart Fail.
20:1732–1734. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Mbroh J and Poli S: 2021 European Heart
Rhythm Association Practical Guide on the use of non-vitamin K
antagonist oral anticoagulants in patients with atrial
fibrillation: comment. Europace. 23:16852021. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Miller KD, Nogueira L, Mariotto AB,
Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel
RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J
Clin. 69:363–385. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Zaorsky NG, Churilla TM, Egleston BL,
Fisher SG, Ridge JA, Horwitz EM and Meyer JE: Causes of death among
cancer patients. Ann Oncol. 28:400–407. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Russo AM: Anticoagulation in cancer
patients with atrial fibrillation or atrial flutter. JACC
CardioOncol. 2:755–757. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Piccini JP, Xu H, Cox M, Matsouaka RA,
Fonarow GC, Butler J, Curtis AB, Desai N, Fang M, McCabe PJ, et al:
Adherence to guideline-directed stroke prevention therapy for
atrial fibrillation is achievable. Circulation. 139:1497–1506.
2019. View Article : Google Scholar : PubMed/NCBI
|
